Email:
sales@chinesepeptide.com
Apr 24, 2023
March 11th, 2021, the road show project of Chinese Peptide Company-''A 100-year Journey of Peptide Therapeutics: From Insulin to Semaglutide'' was presented in the New Drug Summit held in Hangzhou, China which attracted extensive attention from the pharmaceutical industry audiences.
Dr. Henry Ji, Director of R&D and Project Management Department of CPC introduced the century-old development of peptide drugs, the evolution of insulin and its analogs, and three GLP-1 receptor agonists to the audience.
It is 100 years since insulin was isolated in 1921 by Canadian doctor Sir Frederick Grant Banting and his collaborators, the report said. Insulin has saved countless lives. Now, after the painstaking observation and research of countless scientists, there are growing numbers of peptide drugs. By 2019, the market size has occupied 5% of the global pharmaceutical market, and the field of peptide drugs therapeutics is also becoming much more extensive.
With the launch of the world’s first insulin, Eli Lilly continues to expand in the field of diabetes, from various generations of insulin products to SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1RA(glucagon-like peptide-1 receptor agonist), as well as into oncology, immunity, neurodegeneration, pain and other areas. Novo Nordisk is given priority to with diabetes drug, quickly to seize the market with GLP-1RA Liraglutide, Semaglutide (injection, oral);at the same time, with the maturing of biotechnology and peptide synthesis technology, various type of peptide drugs have been developed and applied to clinical, peptide drugs currently has been widely used in diseases such as cancer, hepatitis, diabetes, AIDS prevention, diagnosis and treatment, become the hotspot in the field of medical research.
New opportunities bring new challenges. Chinese Peptide Company is the world’s integrated CRO/CDMO Peptide Partner, it is also the 1st GMP Peptide Facility Audited by FDA in Asia.
Founded in 2001, Chinese Peptide Company is a globally recognized peptide company and leading CRO/CDMO specializing in synthetic peptide production. We work directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. We boast the largest research peptide facility in the world, which successfully has undergone multiple FDA inspections and audits by global pharma organizations. Chinese Peptide Company has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing. We provide milligram to multi-kilogram quantities of CGMP and research-grade peptides with purities of up to 99%. Our expertise in CGMP peptide production ensures that our customers receive peptides of the highest quality.
OUR CERTIFICATIONS AND AUDITS INCLUDE:
FDA, EMA, MFDS, NMPA, PMDA
20,000 ㎡ new GMP building
19 isolated synthesis suites,19 isolated purification suites
Enables several multi-Kg batch size commercial projects at the same time
Has capacity of producing 500kg GMP peptide a year
Reactor 1000L, 2~500 liter, Lyo 20 m2, column up to 20''
